MOESM2 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max Topp, Nicola Gökbuget, Patrick Baeuerle, Peter Kufer, Andreas Wolf & Matthias Klinger
Additional file 2. Available patient numbers (N) for analysis of distribution profiles of neutrophils, thrombocytes, T cells and B cells in Fig. 2.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.